Clinical-stage leverage Arch Oncology is a clinical-stage immuno-oncology company with AO-176 in Phase 1/2 for solid tumors and multiple myeloma, presenting opportunities to partner for late-stage trials, combination regimens, or strategic licensing as they advance.

CD47 expertise Specialization in next-generation anti-CD47 antibodies positions Arch Oncology as a potential collaborator or supplier for companies seeking complementary CD47 programs or combination strategies, including safety and efficacy optimization in tumor-selective contexts.

Strategic partnerships Existing collaboration with Merck and a robust fundraising history signal openness to alliances, co-development, or supply arrangements with pharma partners seeking access to immuno-oncology platforms or novel IO mechanisms.

Strong funding runway With substantial funding and a Series C round totaling around 105 million and overall funding of 250 million, Arch Oncology has financial backing to support expanded clinical development, enabling sales conversations around scalable manufacturing, CRO partnerships, or commercialization planning.

Global talent footprint Distributed R&D footprint with headquarters in California and a research lab in Missouri, plus leadership depth, indicates capacity for multi-regional trial management and regional partner engagement to accelerate global trial execution and access.